Please ensure Javascript is enabled for purposes of website accessibility

Here's Why CRISPR Therapeutics Stock Fell Today

By Cory Renauer – Updated Apr 21, 2019 at 11:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Wall Street analyst isn't too optimistic about the company's lead candidate.

What happened

Shares of CRISPR Therapeutics (CRSP -0.79%), the first clinical-stage company developing CRISPR-based drugs, fell 15.9% in early morning trading after a Wall Street analyst downgraded the stock to sell. CRISPR's price was down 12.5% as of 11:28 a.m. EST on Monday.

So what 

A Citigroup analyst cited two significant issues when he downgraded shares of the stock to sell. The company's lead candidate, CTX001, is intended to treat patients with the same hemoglobin problems as new drug candidates much further along the development timeline. CRISPR didn't start enrolling patients until late 2018, but LentiGlobin from bluebird bio (BLUE -1.48%) could earn approval in the EU later this year. An application in the U.S. isn't far behind, either.

Man in a suit watching money fly out of his pocket and into a hole in the floor

Image source: Getty Images.

There could also be a problem with CTX001's mode of action. CRISPR Therapeutics' lead candidate works by cleaving the BCL11A gene, which is involved in halting the production of fetal hemoglobin shortly after birth. While this might be a way to get fetal hemoglobin started again, it might not be the best option, because dysregulation of BCL11A has been associated with lymphoid malignancies. 

Now what

LentiGlobin doesn't snip out a gene or boost fetal hemoglobin, instead, it installs a new gene that allows sickle cell patients to produce adult hemoglobin that doesn't sickle as easily. We'll probably find out how well this approach works long before we know much more about CTX001's potential.

CRISPR Therapeutics will probably have interim results for CTX001 available for review by the end of the year. This program's being partially funded by CRISPR's collaboration partner, Vertex Pharmaceuticals, which should limit the losses if it flops.

Check out all our earnings call transcripts.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio. The Motley Fool owns shares of CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Crispr Therapeutics Ag Stock Quote
Crispr Therapeutics Ag
$54.36 (-0.79%) $0.43
Bluebird Bio Stock Quote
Bluebird Bio
$7.67 (-1.48%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.